Spinogenix has reported that its Phase II trial of SPG601 for Fragile X Syndrome (FSX) has met its primary goal, according to Clinical Trials Arena. FXS is a genetic disorder that causes intellectual and cognitive disabilities and is caused by a defect in the FMR1 gene on the X chromosome. FXS most commonly affects males. Currently there are no approved treatments available for FXS.
The placebo-controlled trial conducted at the Cincinnati Children’s Hospital Medical Center targeted high-frequency gamma band activity in the brain to reduce electroencephalogram, or EEG, abnormalities which affects learning and memory functions. The therapy aims to increase activation of calcium-activated potassium channels to reduce symptoms common of FXS.
The trial’s results showed decreases of gamma band activity affecting common behaviors associated with FXS, reaching topline results.
The founder and CEO of Spinogenix Stella Sarraf, MD, commented that this exciting finding may lead to the development of the first ever FXS treatment and provide patients with options to improve their qualities of life.
Source: Clinical Trials Arena
